Cash
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive196AccountSocial
MARKETSPERPSLIVE196
Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
Series Image
  1. Medicine

Will the FDA approve retatrutide?



Chance

Before Jul 1, 2027
18%

Before Jul 1, 2027

18%

Before Jan 1, 2028
70%

Before Jan 1, 2028

70%

Before Jul 1, 2028
85%

Before Jul 1, 2028

85%

2 more

Will the FDA approve retatrutide?

Before Jan 1, 2027

Odds
4% chance
Max payout
Dec 31, 2026
$0
$69,998 vol